Atta-ur-Rahman, Professor Emeritus, International Center for Chemical and Biological Sciences (H. E. J. Research Institute of Chemistry and Dr. Panjwani Center for Molecular Medicine and Drug Research), University of Karachi, Pakistan, was the Pakistan Federal Minister for Science and Technology (2000-2002), Federal Minister of Education (2002), and Chairman of the Higher Education Commission with the status of a Federal Minister from 2002-2008. He is a Fellow of the Royal Society of London (FRS) and an UNESCO Science Laureate. He is a leading scientist with more than 1283 publications in several fields of organic chemistry. Muhammad Choudhary, PhD, is a Professor of the International Center for Chemical and Biological Sciences, (H. E. J. Research Institute of Chemistry and Dr. Panjwani Center for Molecular Medicine and Drug Research), University of Karachi, Pakistan. He is a member of the Royal Society of Chemistry, London; American Chemical Society; International Union of Pure and Applied Chemistry (IUPAC); American Society of Pharmacology; New York Academy of Sciences; Federation of Asian Chemical Societies (FACS); and he serves on the executive board of the Asian Network of Research on Anti Diabetic Plants (ANRAP). He is a recipient of the National Book Foundation's Prize for Chemistry and the Economic Cooperation Organization (ECO) Award in Education, 2006, given by the President of Azerbaijan. He has published 24 books, more than 570 papers, and 20 patents.

"... comprehensive compilation of the current knowledge about Alzheimer's disease…recommended to anyone who will be working intensively on the subject…" (translated from German) --MTA Dialog

• 1. Pharmacotherapy of Alzheimer's Disease: Current State and Future Perspectives2. Challenges in Designing Therapeutic Agents for Treating Alzheimer’s Disease-from Serendipity to Rationality3. Enzyme Inhibitors Involved in the Treatment of Alzheimer’s Disease4. Towards Small Molecules as Therapies for Alzheimer’s Disease and Other Neurodegenerative Disorders5. Multifunctional Enzyme Inhibition for Neuroprotection - A Focus on MAO, NOS, and AChE Inhibitors6. Specific Cholinesterase Inhibitors: A Potential Tool to Assist in Management of Alzheimer Disease7. Role of Acetylcholinesterase Inhibitors and Alzheimer Disease8. Research Strategies Developed for the Treatment of Alzheimer’s Disease. Reversible and Pseudo-Irreversible Inhibitors of Acetylcholinesterase: Structure-Activity Relationships and Drug Design9. Modulation of BACE1 Activity as a Potential Therapeutic Strategy for Treating Alzheimer’s Disease10. BACE1 Inhibitors: Attractive Therapeutics for Alzheimer’s Disease11. Combining BACE1 Inhibition with Metal Chelation as Possible Therapy for Alzheimer’s Disease12. Somatostatin Receptor-4 Agonists as Candidates for Treatment of Alzheimer’s Disease13. Neprilysin Inhibitors Provide Insight into its Specificity and Therapeutic Potential14. Targeting the GSK3β/β-catenin Signaling to Treat Alzheimer´s Disease: Plausible or Utopic?15. Targets and Small Molecules Against Tauopathies. Part 1: From Genes to Soluble, Aggregation-Prone Tau Proteins16. Nanomedicine Based Drug Targeting in Alzheimer’s Disease: High Impact of Small Carter

Atta-ur-Rahman, Professor Emeritus, International Center for Chemical and Biological Sciences (H. E. J. Research Institute of Chemistry and Dr. Panjwani Center for Molecular Medicine and Drug Research), University of Karachi, Pakistan, was the Pakistan Federal Minister for Science and Technology (2000-2002), Federal Minister of Education (2002), and Chairman of the Higher Education Commission with the status of a Federal Minister from 2002-2008. He is a Fellow of the Royal Society of London (FRS) and an UNESCO Science Laureate. He is a leading scientist with more than 1283 publications in several fields of organic chemistry. Muhammad Choudhary, PhD, is a Professor of the International Center for Chemical and Biological Sciences, (H. E. J. Research Institute of Chemistry and Dr. Panjwani Center for Molecular Medicine and Drug Research), University of Karachi, Pakistan. He is a member of the Royal Society of Chemistry, London; American Chemical Society; International Union of Pure and Applied Chemistry (IUPAC); American Society of Pharmacology; New York Academy of Sciences; Federation of Asian Chemical Societies (FACS); and he serves on the executive board of the Asian Network of Research on Anti Diabetic Plants (ANRAP). He is a recipient of the National Book Foundation's Prize for Chemistry and the Economic Cooperation Organization (ECO) Award in Education, 2006, given by the President of Azerbaijan. He has published 24 books, more than 570 papers, and 20 patents.

"... comprehensive compilation of the current knowledge about Alzheimer's disease…recommended to anyone who will be working intensively on the subject…" (translated from German) --MTA Dialog

• 1. Pharmacotherapy of Alzheimer's Disease: Current State and Future Perspectives2. Challenges in Designing Therapeutic Agents for Treating Alzheimer’s Disease-from Serendipity to Rationality3. Enzyme Inhibitors Involved in the Treatment of Alzheimer’s Disease4. Towards Small Molecules as Therapies for Alzheimer’s Disease and Other Neurodegenerative Disorders5. Multifunctional Enzyme Inhibition for Neuroprotection - A Focus on MAO, NOS, and AChE Inhibitors6. Specific Cholinesterase Inhibitors: A Potential Tool to Assist in Management of Alzheimer Disease7. Role of Acetylcholinesterase Inhibitors and Alzheimer Disease8. Research Strategies Developed for the Treatment of Alzheimer’s Disease. Reversible and Pseudo-Irreversible Inhibitors of Acetylcholinesterase: Structure-Activity Relationships and Drug Design9. Modulation of BACE1 Activity as a Potential Therapeutic Strategy for Treating Alzheimer’s Disease10. BACE1 Inhibitors: Attractive Therapeutics for Alzheimer’s Disease11. Combining BACE1 Inhibition with Metal Chelation as Possible Therapy for Alzheimer’s Disease12. Somatostatin Receptor-4 Agonists as Candidates for Treatment of Alzheimer’s Disease13. Neprilysin Inhibitors Provide Insight into its Specificity and Therapeutic Potential14. Targeting the GSK3β/β-catenin Signaling to Treat Alzheimer´s Disease: Plausible or Utopic?15. Targets and Small Molecules Against Tauopathies. Part 1: From Genes to Soluble, Aggregation-Prone Tau Proteins16. Nanomedicine Based Drug Targeting in Alzheimer’s Disease: High Impact of Small Carter